Home · Blog · GLP-1 side effects compared

GLP-1 side effects compared: what three FDA labels show for four products

Safety · Analysis Nausea, vomiting, diarrhea and quit rates for Wegovy, Zepbound, Foundayo and the Wegovy pill, from each label’s own tables.

Released: Last reviewed:

Short answer · November 8, 2026

All four products compared here mostly cause stomach side effects. In their label tables, nausea hit 44% of Wegovy 2.4 mg patients (16% on placebo), 25% to 29% on Zepbound (8%) and 26% to 35% on Foundayo (10%). Between 4.8% and 10% stopped because of side effects.

Choosing between Wegovy, Zepbound, Foundayo and the Wegovy pill usually comes down to how likely you are to feel sick while the dose rises. The FDA labels answer with tables built in different ways. Here they are side by side.

We are not repeating our general GLP-1 side-effect guide or our look at real-world side-effect reports. Everything below comes from the current prescribing information on DailyMed, read November 8, 2026: Wegovy (revised 06/2026, one label covering the injection and the tablets), Zepbound (revised 08/2026) and Foundayo (revised 07/2026).

The label numbers, side by side

Each label has a section 6.1 table of adverse reactions from its placebo-controlled weight-management trials. Wegovy’s Table 3 pools three trials with 2,116 adults on 2.4 mg and 1,261 on placebo, treated for up to 68 weeks. Zepbound’s Table 1 pools Study 1 and Study 2, with 2,519 adults on the drug for up to 72 weeks, split by dose. Foundayo’s Table 1 pools Trials 1 and 2, with 3,155 adults for up to 72 weeks, also split by dose.

Common side effects in the weight-management trials, from each FDA label’s adverse-reaction table (labels read November 8, 2026). Percent of patients; a dash means the symptom is not in that table.
Side effectWegovy 2.4 mg injectionPlaceboZepbound 5 / 10 / 15 mgPlaceboFoundayo 5.5 / 9 / 17.2 mgPlacebo
Nausea44%16%25% / 29% / 28%8%26% / 34% / 35%10%
Diarrhea30%16%19% / 21% / 23%8%21% / 23% / 25%11%
Vomiting24%6%8% / 11% / 13%2%13% / 21% / 24%4%
Constipation24%11%17% / 14% / 11%5%20% / 27% / 24%9%
Abdominal pain20%10%9% / 9% / 10%5%13% / 14% / 14%7%
Indigestion (dyspepsia)9%3%9% / 9% / 10%4%12% / 16% / 13%4%
Fatigue11%5%5% / 6% / 7%3%6% / 7% / 9%4%
Headache14%10%— / — / ——8% / 9% / 9%7%
Table basisTable 3: 3 trials, up to 68 weeks; listed if ≥2% and above placeboTable 1: Studies 1 and 2, up to 72 weeks; ≥2% and above placeboTable 1: Trials 1 and 2, up to 72 weeks; ≥5% and above placebo

Nausea is the most common reaction in all three tables, followed by some mix of diarrhea, vomiting and constipation. Vomiting climbs with the dose in Zepbound and Foundayo, and so does Foundayo’s nausea (Zepbound’s peaks at 10 mg), while constipation does not: Zepbound’s constipation rate is highest at 5 mg (17%) and lowest at 15 mg (11%). The Wegovy label’s own text gives vomiting as 25% while its table shows 24%; we use the table.

Why you can’t compare the tables cell by cell

It is tempting to read across a row and declare a winner. Four things get in the way.

  • Different cut-offs. Wegovy and Zepbound list any reaction seen in at least 2% of patients and more often than placebo. Foundayo lists only reactions seen in at least 5%, so a milder symptom can be missing from its table simply because of the threshold. Headache is absent from Zepbound’s table, meaning it did not pass that label’s 2%-and-above-placebo test.
  • Different placebo groups. Placebo nausea was 16% in the Wegovy trials, 8% in Zepbound’s and 10% in Foundayo’s. The same raw percentage means something different against each baseline.
  • Different trials and patients. These were separate programs with their own durations, populations and titration schedules. Foundayo’s pool includes adults with and without type 2 diabetes, and its label notes the safety data come from an investigational orforglipron formulation shown as equivalent Foundayo doses.
  • No head-to-head design. None of these tables comes from a trial that randomised patients between the drugs.

The fairest single number each label supports is the gap over its own placebo group. Here is that arithmetic at the highest labelled dose.

Placebo-subtracted percentage points at the highest labelled dose (our arithmetic from the label tables above)
Side effectWegovy 2.4 mgZepbound 15 mgFoundayo 17.2 mg
Nausea44 − 16 = 2828 − 8 = 2035 − 10 = 25
Vomiting24 − 6 = 1813 − 2 = 1124 − 4 = 20
Diarrhea30 − 16 = 1423 − 8 = 1525 − 11 = 14
Constipation24 − 11 = 1311 − 5 = 624 − 9 = 15

On this measure Wegovy 2.4 mg and Foundayo 17.2 mg sit close together for nausea (28 and 25 points), Foundayo shows the largest vomiting gap (20 points), and Zepbound 15 mg shows the smallest constipation gap (6 points). Zepbound’s nausea gap is actually largest at 10 mg (29 − 8 = 21). Treat differences of a few points as noise across separate trials.

How many people stopped because of side effects

Quitting is the outcome that matters most to your wallet, because the month you stop is a month you paid for. Each label reports permanent discontinuation due to adverse reactions.

Stopped treatment because of side effects, per each label (percent of patients, drug vs placebo)
DrugAny adverse reactionGastrointestinal reactionSelf-pay price (read date)
Wegovy 2.4 mg injection6.8% vs 3.2%4.3% vs 0.7%$349/mo pen at NovoCare; $199 for two 0.25/0.5 mg fills for new patients through Dec 31, 2026 (Oct 15)
Wegovy 25 mg tablets6.9% vs 5.9%3.4% vs 2%$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) at NovoCare (Oct 15)
Zepbound 5 / 10 / 15 mg4.8% / 6.3% / 6.7% vs 3.4%1.9% / 3.3% / 4.3% vs 0.5%$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with refills within 45 days) per 28-day fill, LillyDirect KwikPen or vial (Oct 15)
Foundayo 5.5 / 9 / 17.2 mg6% / 9% / 10% vs 3%3% / 6% / 6% vs 0.7%$149–$299 on archived LillyDirect pages dated Sept 25, 2026; some reduced prices end Dec 31, 2026

Subtracting placebo again: about 3.6 extra people in 100 stopped Wegovy injections because of side effects (6.8 − 3.2), 3.3 extra stopped Zepbound 15 mg (6.7 − 3.4), and 7 extra stopped Foundayo 17.2 mg (10 − 3). The Wegovy tablet gap was 1 point (6.9 − 5.9), but it comes from a single trial of 204 adults on the 25 mg tablet, so it is the least certain figure here.

The Wegovy pill has no symptom table of its own

The Wegovy label does not print a separate per-symptom table for the tablets. It says that in the 25 mg tablet trial “the types and frequency of common adverse reactions were similar to those listed in Table 3,” the injection table. It does give a few tablet-specific figures: severe gastrointestinal reactions in 2% of tablet patients versus 0% on placebo, dysesthesia (unusual skin sensations) in 5% versus none, and gallstones in 2.5% versus 1%. Don’t borrow the injection percentages and present them as pill data.

What the labels share

Every one of these labels carries a boxed warning for thyroid C-cell tumors and lists the same two contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a serious allergic reaction to the drug or its ingredients. Foundayo’s boxed warning is based on the drug class; its label says orforglipron is not active in rats or mice and did not cause tumors in them. Our contraindications page covers who should not start a GLP-1 at all.

Where the rules differ

Where the labels differ on practical safety rules (labels read November 8, 2026)
RuleWegovy injectionWegovy tabletsZepboundFoundayo
Oral birth-control pillsNo label instructionNo label instructionSwitch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increaseSame advice, for 30 days after starting and after each dose increase
Planning a pregnancyStop at least 2 months before a planned pregnancyStop when pregnancy is recognizedStop when pregnancy is recognized; use effective contraception during treatment
Missed doseTake it if the next dose is more than 2 days away; otherwise skip. Two or more missed in a row: restart at a lower doseSkip it; take the next tablet the following dayTake within 4 days (96 hours); otherwise skipTake as soon as possible, never double up; 7 or more missed in a row: restart at a lower dose

The birth-control rule is easy to miss. Zepbound and Foundayo can make oral contraceptive pills less reliable, and the window restarts with every dose increase, so a normal titration means several stretches of backup contraception. The table above gives each label’s missed-dose rule.

Side effects and the bill

Stomach side effects often lead prescribers to slow the dose increase or hold a patient at a lower dose. On brand self-pay pricing that changes the bill, because price depends on dose. Using prices read October 15, 2026: holding at Zepbound 5 mg instead of moving to 10 mg costs $399 instead of $449 per 28-day fill with on-time refills, $50 less. On the Wegovy pill, staying at 4 mg instead of 9 mg costs $199 instead of $299, $100 less. Foundayo’s archived LillyDirect prices put 5.5 mg at a temporarily reduced $199 and 9 mg at $299, with the reduced prices ending December 31, 2026.

Compounded programs with flat pricing do not move with dose. NexLife, for example, charges $129 a month for compounded tirzepatide month to month at every dose as of November 6, 2026. But compounded semaglutide and tirzepatide have no FDA label and therefore no adverse-reaction table at all. They are made with the drug in Wegovy or Zepbound, not the same product, and the trial numbers above do not transfer to them automatically. FDA’s GLP-1 page, current as of October 1, 2026, counted 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026, and describes dosing errors in which patients measured the wrong amount. Our compounding risks page explains what that means.

What this means for you

  • Expect nausea to be the main issue on any of the four, most often while the dose is rising.
  • If you have struggled with vomiting before, ask your clinician about the slower end of the titration schedule; vomiting rose most steeply with dose in the Foundayo and Zepbound tables.
  • If you take birth-control pills, plan for backup contraception on Zepbound or Foundayo.
  • Use the placebo-subtracted figures, not the raw ones, when comparing drugs, and remember they come from separate trials.
  • If injections or refrigeration are a problem, the two pills avoid them; see our note on GLP-1 shipments that arrive warm for the storage side.

Report any serious side effect to your prescriber and to FDA through MedWatch, whether the product was brand or compounded.

Editor’s pick · 94/100 on our v4.1 methodology

NexLife

$129/mo compounded tirzepatide month to month, $115/mo on a 12-month plan; compounded semaglutide $109/mo, or $95/mo on 12 months. Same price at every dose, no membership (prices as of November 6, 2026).

  • Clinician review and medical guidance (NexLife Medical Group), a GLP-1 nutrition plan, a 1:1 wellness-coach call, 24/7 support, free expedited shipping
  • Plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA)
  • Cancellations take effect after 30 days; compounded drugs are not FDA-approved

FAQ

Which weight-loss GLP-1 causes the least nausea?

The labels cannot settle it, because the trials were separate and used different placebo groups. Measured against their own placebo, nausea was 28 points higher on Wegovy 2.4 mg, 20 points on Zepbound 15 mg (21 at 10 mg) and 25 points on Foundayo 17.2 mg. Those gaps are close enough that individual response and dose speed matter more.

Does the Wegovy pill have fewer side effects than the injection?

The label does not show that. It says common side effects with the 25 mg tablet were similar in type and frequency to the injection table, without a separate symptom table. Discontinuation for side effects was 6.9% on the tablet versus 5.9% on placebo, from a single trial of 204 adults, so the comparison is uncertain.

Why does Foundayo’s side-effect table look different?

Foundayo’s table lists only reactions seen in at least 5% of patients and more often than placebo, while Wegovy and Zepbound use a 2% cut-off. Its safety data also come from an investigational orforglipron formulation shown as equivalent Foundayo doses. So some symptoms are missing from its table for reasons unrelated to how often they occur.

Do compounded semaglutide and tirzepatide have the same side effects?

Nobody can say from label data, because compounded versions are not FDA-approved and have no label or adverse-reaction table. They are made with the drug in Wegovy or Zepbound, not the same product. FDA counted 990 reports for compounded semaglutide and over 730 for compounded tirzepatide through May 31, 2026, including dosing-error cases.

Who should not take any of these four drugs?

All three labels list the same contraindications: a personal or family history of medullary thyroid carcinoma or MEN 2, and a serious allergic reaction to the drug or its ingredients. All carry a boxed warning for thyroid C-cell tumors. The Wegovy label also says to stop at least two months before a planned pregnancy.

Sources

  1. DailyMed — Wegovy (semaglutide) injection and tablets prescribing information, revised 06/2026 (read November 8, 2026)
  2. Novo Nordisk — Wegovy prescribing information (PDF) (read November 8, 2026)
  3. DailyMed — Zepbound (tirzepatide) prescribing information, revised 08/2026 (read November 8, 2026)
  4. Eli Lilly — Zepbound prescribing information (PDF) (read November 8, 2026)
  5. DailyMed — Foundayo (orforglipron) tablets prescribing information, revised 07/2026 (read November 8, 2026)
  6. Eli Lilly — Foundayo prescribing information (PDF) (read November 8, 2026)
  7. U.S. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026) (read November 8, 2026)
  8. NovoCare — Wegovy self-pay offer (pen and pill prices) (read October 15, 2026)
  9. Lilly — Zepbound coverage and savings (self-pay prices) (read October 15, 2026)
  10. LillyDirect — Foundayo self-pay prices (archived September 25, 2026) (read October 15, 2026)
  11. NexLife — Tirzepatide plans (prices as of November 6, 2026) (read November 8, 2026)
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.